TY - JOUR
T1 - Hormone replacement therapy in the menopause
T2 - A pro opinion
AU - Smith, Harriet O.
AU - Kammerer-Doak, Dorothy N.
AU - Barbo, Dorothy M.
AU - Sarto, Gloria E.
PY - 1996
Y1 - 1996
N2 - The preponderance of data support the benefits of HRT in estrogen-deprived and menopausal women to reduce the risks of osteoporosis and cardiovascular disease and to enhance quality of life and life expectancy. Controversies exist with regards to the risk-benefit ratio in women with a history of estrogen-dependent gynecologic tumors or breast cancer. Until these issues are resolved, physicians must carefully weigh, on an individual basis for each patient, the potential risks against the known benefits. Women should be counseled regarding the benefits of exercise, weight control, breast feeding, and cessation of cigarette smoking or excessive alcohol to reduce their risks of cancer, cardiac disease, and/or osteoporosis. HRT is not a panacea for an unhealthy lifestyle. When ERT is contraindicated, viable alternatives to retard bone loss and/or control vasomotor symptoms include calcium supplementation and progestin therapy. The role of tamoxifen as an alternative HRT in women at increased risk for breast cancer development is currently under investigation.
AB - The preponderance of data support the benefits of HRT in estrogen-deprived and menopausal women to reduce the risks of osteoporosis and cardiovascular disease and to enhance quality of life and life expectancy. Controversies exist with regards to the risk-benefit ratio in women with a history of estrogen-dependent gynecologic tumors or breast cancer. Until these issues are resolved, physicians must carefully weigh, on an individual basis for each patient, the potential risks against the known benefits. Women should be counseled regarding the benefits of exercise, weight control, breast feeding, and cessation of cigarette smoking or excessive alcohol to reduce their risks of cancer, cardiac disease, and/or osteoporosis. HRT is not a panacea for an unhealthy lifestyle. When ERT is contraindicated, viable alternatives to retard bone loss and/or control vasomotor symptoms include calcium supplementation and progestin therapy. The role of tamoxifen as an alternative HRT in women at increased risk for breast cancer development is currently under investigation.
UR - http://www.scopus.com/inward/record.url?scp=0029846094&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029846094&partnerID=8YFLogxK
U2 - 10.3322/canjclin.46.6.343
DO - 10.3322/canjclin.46.6.343
M3 - Review article
C2 - 8917020
AN - SCOPUS:0029846094
SN - 0007-9235
VL - 46
SP - 343
EP - 363
JO - Ca-A Cancer Journal for Clinicians
JF - Ca-A Cancer Journal for Clinicians
IS - 6
ER -
